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Abstract
Most cases of hemolytic disease of the newborn associated with anti-Jra are mild. However, rare cases of hydrops fetalis
and severe anemia have been reported. We treated a neonate with anemia who was born with maternal anti-Jra, which
were detected in the umbilical cord plasma. The Jra antigens in the neonate core blood red blood cells (RBCs) exhibited
extremely weak reactivity to PEG-IAT, an anti-Jra reagent. However, upon re-examination of Jra antigen using PEG-IAT at
3 months postpartum, positivity was observed. Thereafter, upon performing PCR-SSP analysis of blood relatives targeting
ABCG2 at positions 376 and 421, we found that the mother was Jr(a−) with 376 T homozygosity, whereas the father was
Jr(a+) with 376 C homozygosity and a carrier of a 421 C > A mutation. The first sibling, like the propositus, was Jr(a+),
exhibiting 376 CT heterozygosity. However, the first sibling carried a 421 C > A mutation, whereas the propositus had no
mutation at position 421. Setting the normal Jra (a+) type (376 C, 421 C) to 100 %, we identified the amount of Jra in RBC
using FCM to be 82 % in the father, 31 % in the first sibling, and 69 % in the propositus. Furthermore, upon comparing
peripheral blood and myelograms of the neonate at the time of birth, we found a low myeloid cells/erythroid cells ratio,
undifferentiated erythroblasts, and reduced megakaryocytes. On the basis of these findings, we suggest that cell surface
antigen is involved in the HDN caused by anti-Jra, and that a cytodifferentiation abnormality is present in the
hematopoietic system.
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Background
More than 300 known blood group antigens are present
in RBC, of which Jra is present at a very high frequency.
An antibody directed to the Jra was first described in
1970 by Stroup and MacIlroy [1]. In Japan, there is a
relatively high frequency of Jr(a−) individuals; approxi-
mately 0.06 % [2, 3]. In 2012, it was discovered that the
ATP-binding cassette G2 (ABCG2/CD338) in the ATP-
binding cassette transporter family carries the Jra, and
the Jra (JR1) was adopted as the 32nd human blood
group system by the International Society for Blood
Transfusions (ISBT) [4–7]. The incidence of hemolytic
disease of the newborn due to anti-Jra is low, with ma-
jority of cases being mild. However, a couple of cases
have been reported in which the patient developed
hydrops fetalis [8–11]. In the present study, we treated a
newborn who was hospitalized for transient tachypnea
and presented with anemia and leukocytosis, which was
believed to be associated with the presence of anti-Jra.
To determine the cause, we assessed the amount of Jra
and ABCG2 in the RBC.
Case presentation
Perinatal and family history
The mother was gravida 5 para 2, including three mis-
carriages. On examination of irregular antibodies at
16 weeks of pregnancy with the first child (G4P1), the
mother was Jr(a−) and had anti-Jra (antibody titer of
1:512). When pregnant with the second child (G5P2),
the mother had an anti-Jra antibody titer of 1:64 at
20 weeks of pregnancy, and subsequently 1:256 at
27 weeks (IgG1 subclass). No other antibodies against
blood group antigens were identified.
The first child was a girl, delivered at 36 weeks and
3 days of gestational age by Cesarean section at a different
hospital due to breech presentation. The characteristics of
the neonate included a birth weight of 2590 g, a height of
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44.0 cm, a chest circumference of 32.0 cm, a head circum-
ference of 34.0 cm, Apgar scores of 8 points at 1 min and
10 points at 5 min, and a placental weight of 560 g.
At 2 days of age, blood sampling was performed on suspi-
cion of hyperbilirubinemia due to anti Jra, revealing a total
bilirubin level of 9.3 mg/dL, with an unconjugated bilirubin
level of 0.39 μg/dL. Therefore, the newborn was discharged
from the hospital without phototherapy.
The second child was a girl delivered at 37 weeks
and 6 days of gestational age, with a birth weight of
2808 g, a height of 49.0 cm, a head circumference of
32.5 cm, a chest circumference of 32.0 cm, Apgar
scores of 7 points at 1 min and 8 points at 5 min, and a
placental weight of 755 g.
From 35 weeks and 5 days of gestational age, the
mother was administered ritodrine hydrochloride at a
dose of 200 μg/min upon diagnosis of threatened prema-
ture delivery, and the baby was delivered by Cesarean
section. Tachypnea and expiratory grunting were ob-
served at birth, and with a SpO2 of 80 % persisting with
room air, the baby was hospitalized.
The neonate was characterized by absence of bulging
anterior fontanel, pallid skin, absence of cyanosis, grunt-
ing on chest auscultation, tachypnea, soft abdomen, and
regular bowel sounds. Reduced translucency and partial
dilatation were observed on chest radiography, and the
neonate was diagnosed with transient tachypnea of
newborn. After hospital admission, oxygen within the
incubator was kept below 40 %, which improved grunting
and reduced the respiratory rate. Furthermore, oxygen
therapy was slowly decreased, and discontinued at 1 day
of age. Blood sampling at the time of hospital admission
revealed a WBC count of 31,500/μL (segmented neutro-
phils, 61.8 %; lymphocytes, 28.0 %; monocytes, 7.5 %;
eosinophils, 1.8 %; basophils, 0.9 %); RBC, 2.20 × 106/μL;
Hb, 8.4 g/dL; Hct, 25.8 %; MCV, 117.3 fl; MCH, 38.2 pg;
MCHC, 32.6 g/dL; Plt, 297 × 103/μL; reticulocytes, 80.9 %;
T-bil, 1.9 mg/dL; D-bil, 0.7 mg/dL; LDH, 355 IU/L; AST,
23I U/L; ALT, 8 IU/L; BUN, 7.9 mg/dL; Creat, 0.54 mg/
dL; CPK, 92 IU/L; UA, 7.0 mg/dL; Na, 140.4 mEq/L; K,
4.82 mEq/L; Cl, 105.8 mEq/L; Ca, 10.4 mg/dL; IP, 5.3 mg/
dL; Fe, 140 μg/dL; CRP, 0.30 mg/dL; IgM, 7 mg/dL;
haptoglobin < 10, and ferritin, 255 ng/mL.
Examination for irregular cord blood antibodies revealed
anti-Jra (antibody titer of 1:8); meanwhile, no other irregu-
lar antibodies were observed. The results of direct anti-
globulin testing were negative. Upon examination using a
20 % PEG-IAT, cord RBC and maternal plasma reactivity
were negative, but PEG-IAT with anti-Jra reagent revealed
very weak binding. Thus, we refrained from determining
the Jra type.
Blood sampled at 6 h and 24 h postpartum revealed
bilirubin levels of 2.9 mg/dL and 2.8 mg/dL respectively,
indicating no increase, and thereby phototherapy and
exchange transfusions were not performed. Thereafter,
hyperbilirubinemia was not observed, and at 13 days of
age, the infant was discharged from the hospital.
Following discharge, we observed an increase of Hb to
14.1 g/dL and Hct to 39.1 % at three months. Haptoglobin
was <10 mg/dL during treatment, but haptoglobin 2–2 type
increased at 3 months (Fig. 1). Upon re-examination by
PEG-IAT at 3 months using the anti-Jra, the infant’s RBC
exhibited normal reactivity, and Jr(a+) was determined.
With consent from the family and after obtaining
approval from the ethics committee of our hospital
(Tendo Hospital notification 75) for familial blood
group testing and genetic testing, we requested the
Tohoku Block Blood Center to carry out the following
analyses.
Samples and methods
We evaluated the presence of Jra antigen in RBC in a
test tube using three types of monoclonal anti-Jra
(HIRO-133, HIRO-157, and HIRO-248) manufactured
by the Red Cross. Further analyses were performed by
FCM. The FACSCulibur (Becton, Japan ®) was used for
FCM. High-titer, low-avidity (HTLA) anti-Jra were ob-
served, and therefore, to enhance RBC antigen-antibody
reactions, RBC underwent enzymatic treatment with 1 %
ficin (MP Biomedicals ®). Primary antibodies were sensi-
tized at 37 °C for 60 min, after which secondary anti-
bodies (anti-human IgG: Fluorescein Labelled F [ab’]2)
to human IgG (H + L) CODE:BI 4115 (Abliance®) were
diluted 1:20 in PB, and sensitized at 4 °C for 60 min.
Genomic DNA was extracted from whole blood using
DNA Blood Mini Kit (QIAamp Qiagen®, Chuo-ku Japan)
according to the manufacturer’s instruction. For PCT, we
used the Gene Amp PCR System 9700 series (Biosystems®).
Gene analysis was performed by multiplex-PCR with our
uniquely designed primers to detect SNPs in ABCG2 at po-
sitions 34, 337, 376, 421, and 1515 (Table 1). The PCR-1 to
PCR-8 included initial denaturation at 94 °C for 3 min and
35 cycles of denaturation(94 °C, 15 s) and annealing-
extension(59 °C 1 min), followed by final extension at 72 °C
for 5 min. PCR conditions of the PCR9-14 included initial
denaturation at 94 °C for 3 min and 35 cycles of denatur-
ation(94 °C, 15 s) and annealing-extension(60 °C 1 min),
followed by final extension at 72 °C for 5 min using DNA
polymerase(PrimeSTAR GXL, Takara Bio, Inc.). The ob-
tained amplicons were subsequently sequenced using a
cycle sequencing kit (BigDye Terminator, Version 1.1,
Applied Biosystems Carlsbad, CA) and genetic analyzer
(Model 3130xl, Applied Biosystems). After electrophoresis
of the PCR product for 25 min at 200 V using a 7.5 % gel,
the product was stained for 10 min with a solution contain-
ing 5 μL of ethidium bromide per 100 mL of deionized
water, and the presence or absence of each specific band
was evaluated.
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Results
Family blood groups
The mother’s blood group was type O, D + C + c-E-e +,
M-N + S-s +, P1−, Fy(a + b−), Jk(a + b +), Di(a–b+), Jr(a−);
the father’s blood group was type A, D +C + c-E-e +, M-
N + S-s +, P1+, Fy(a + b+), Jk(a + b+), Di(a–b +), Jr (a+);
the first child’s blood group was type A, D + C + c-E-e +,
M-N + S-s +, P1-, Fy(a + b−), Jk(a + b+), Di(a–b+), Jr(a+);
and the proband’s blood group was type O, + C + c-E-e +,
M–N+ S-s +,P1+, Fy(a + b−), Jk(a–b+), Di(a–b+), Jr(a+).
ABCG2 (JR gene) analysis by PCR-SSP (Fig. 2)
Genomic DNA was extracted from the peripheral
blood of family members, and PCR-SSP was used to
examine the presence or absence of genetic base substi-
tutions at positions 376 and 421, which are primarily
believed to affect Jra antigen density. The mother had
Jr(a−) phenotype, exhibiting homozygous substitution of
cytosine (C)—the common base at position 376 —for
thymine (T) (376C > T), whereas no base mutations were
observed at position 421. The father was homozygous
for wild type 376 C/C, with a genetic mutation at pos-
ition 421 C > A. The first child was heterozygous for 376
C/T with a 421 C > A mutation. The second child was
heterozygous for 376 C/T, and unlike the first child, ex-
hibited no mutation at position 421 (421 C/C).
Comparison of the red blood cell antigen density by FCM
Jra antigen densities of family members were com-
pared according to mean fluorescence intensity. When
compared with the mean fluorescence intensity of nor-
mal Jr(a+) (genotype: 376C/C, 421C/C) RBC set to
100 %, the mean intensity was 82 % for the father,
31 % for the first child, and 69 % for the second child
(Fig. 3).
Comparison of peripheral blood and bone marrow
aspirate images taken immediately postpartum and at
4 months postpartum (Fig. 4)
A peripheral blood smear taken at 3 days of age re-
vealed numerous polychromatic erythrocytes, spherocytes,
leptocytes, and poikilocytes. Hypersegmented neutrophils
Fig. 1 Changes in hemoglobin, hematocrit, haptoglobin, and reticulocytes from birth to 4 months postpartum. Hemoglobin and hematocrit levels as well
as haptoglobin were increased after 3 months
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and megathrombocytes were also observed (Fig. 4a). A
peripheral blood smear performed at 1 month revealed a
decline in hypersegmented neutrophils and megathrom-
bocytes; at 4 months, these had disappeared (Fig. 4c). A
bone marrow aspiration performed at 5 days of age re-
vealed a cell count of 100,000/μL (myeloblasts, 0.2 %;
myelocytes, 4.2 %; metamyelocytes, 3.2 %; band cells,
8.6 %; segmented neutrophils, 16.4 %; eosinophils, 1.6 %;
basophils, 0.2 %; lymphocytes, 10.6 %; monocytes, 3.2 %;
polychromatophilic erythroblasts, 28.0 %; orthochromatic
erythroblasts, 23.0 %; and granulocytic/erythroblastic cell
ratio, 0.7 %) with bone marrow hyperplasia. No megakar-
yocytes or macroblasts were observed. Among normo-
blasts, an increase in polychromatic and orthochromatic
erythroblasts was observed in the absence of basophilic
erythroblasts (Fig. 4b). Re-examination by bone marrow
Table 1 Oligonucleotide primers used for PCR
PCR (target) Primer name Nucleotide sequence (5′–3′)
JRA337/376/1515-SSP
PCR-1 (Exon 13) JRA1515-F4 AAGTCAAAGGCAGATGCTTC
PCR-2 (Exon 13) JRA1515-R2 CCTTATCAGAGCAAACAGAG
PCR-3 (Exon 4) JRA376-F4 CCAAGTGGATTATCTGGAGATG
PCR-4 (Exon 4) JRA376-R6 TTGTCTCCTTTGTCTTTTACCAAACCCACTAATACTTTCTTG
PCR-5 (Exon 4) JRA376-R1 CAAACCCACTAATACTTACTTA
PCR-6 (Exon 4) JRA337-R10 TACATTTGAAATTGCCAGGTCA
PCR-7 (Exon 4) GPC4-3 TGTGGCATTGTATCTTGTCCT
PCR-8 (Exon 4) GPC4-4 GTGGCTATCTCGGGAAGAAT
JRA34/421-SSP
PCR-9 (Exon 2) JRA34-F2 TGGTATGGGCCATTCATTG
PCR-10 (Exon 2) JRA34-R7 CATTGGTGTTGCCTCGTGACAT
PCR-11 (Exon 2) JRA34-R10 CTTCGACAGCGCCCCTTCGGATTGGTGTTGCCTCGTGACAC
PCR-12 (Exon 5) JRA421-F4 CTGACAGTGAGAGAAAACTTAA
PCR-13 (Exon 5) JRA421-15 ACTACAACACTACCCGTGAGTGACGGTGAGCGAAAACTTAC
PCR-14 (Exon 5) JRA421-R2 CACTTTATCCAGACCTAACTC-3′
Fig. 2 ABCG2 analysis of the family by PCR-SSP. a 1: Jr(a−) phenotype 376 T/T, 2: Jr(a−) phenotype 376C/T & 1515delC, 3: Jr(a−) or Jr(a+) phenotype 376C/
T, 4: Jr(a−) phenotype 376C/T& 337C > T, 5: mother 376 T/T, 6: father 376C/C, 7: 1st baby 376C/T, 8: 2nd baby 376C/T. b 1: 34G/A 421C/A, 2: 34G/G 421A/A,
3: 34G/A 421C/C, 4: mother 34G/G 421C/C, 5: father 34G/G 421C/A, 6: 1st baby 34G/G 421C/A, 7: 2nd baby 34G/G 421C/C
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aspiration at 4 months, revealed a cell count of 420,000/μL
(myeloblasts, 1.6 %; promyelocytes, 3.4 %; myelocytes,
4.0 %; metamyelocytes, 10.2 %; band cells, 10.8 %; seg-
mented neutrophils, 10.6 %; eosinophils, 1.0 %; basophils,
0 %; lymphocytes, 38.8 %; monocytes, 2.6 %; macroblasts,
0.6 %; basophilic erythroblasts, 0.2 %; polychromatophilic
erythroblasts, 10.2 %; orthochromatic erythroblasts, 0 %;
and granulocytic/erythroblastic cell ratio, 4.3 %), and mega-
karyocytes were present (Fig. 4d).
Discussion
ABCG2 that carries the Jra antigen is located on the long
arm of chromosome 4 (4q22) [6, 7]. It has been con-
firmed that ABCG2 is overexpressed on the surface of
the placental villi, and if the fetal blood group is Jr(a+),
then anti-Jra can be readily stimulated in maternal serum
during pregnancy. The placental weight and gestation age
in weeks for both the first and second child were compar-
able, and therefore, it appears that anti-Jra had little impact
on placenta. Cord blood and peripheral RBC from the
second child typed Jr(a-) immediately postpartum as mea-
sured by PEG-IAT with anti-Jra. However, at 3 months of
age, the results were positive. Furthermore, it is believed
that haptoglobin is not affected by changes in RBC in neo-
nates; however, in the present study, haptoglobin showed a
low value of <10 from birth to 2 months postpartum, which
normalized after 3 months. Maternally derived IgG has a
half-life of 20 days, and the infant’s total IgG titer is lowest
at 3–4 months. This suggests that many cells expressing Jra
antigen were affected by maternally derived anti-Jra, and
that cells with low Jra antigen density may have remained.
Various SNPs within ABCG2 that carry the Jra antigen have
been reported [7, 12, 13], among which 376 C >T and 421
C >A mutations have been found to affect Jra antigen dens-
ity in RBC. It is believed that upon identification of Jra(a−)
and Jr(a + w) phenotypes, attempting gene analysis of gen-
etic bases at positions 376 and 421 is useful when compar-
ing Jra antigen densities [14]. Hence, with the first child
with low antigen density being asymptomatic and the
second child with high antigen density presenting with
symptoms, this demonstrates that RBC antigen density
is involved in the manifestation of symptoms. Upon
bone marrow examination of the second child at 5 days
and 4 months of age, the myeloid cells/erythroid cells
ratio increased from 0.7 to 4.3 %. Furthermore, at 5 days
of age, erythroblast subsets exhibited an extremely high
proportion of polychromatic to orthochromatic eryth-
roblasts, with no immature macroblasts being observed.
Megakaryocytes also showed a considerable decrease at
5 days of age. Peripheral blood at 5 days of age showed
megathrombocytes and hypersegmented leukocytes. It has
recently been indicated that ABCG2 is responsible for
maintaining the undifferentiated state in hematopoietic
stem cells [14, 15]. While undifferentiated hematopoietic
stem cells frequently express ABCG2, most precursor cells
that have differentiated, exhibit decreased levels of ABCG2
expression, and expression is increased in erythroblastic cell
differentiation. Therefore, it is believed that changes in the
bone marrow and peripheral blood inhibited ABCG2 ex-
pression by anti-Jra antibodies, which may have led to
excessive differentiation.
At present, anti-Kell are known to cause HDN from
hematopoietic cellular dysfunction. Immature erythroblasts
in the fetal liver are damaged by phagocytes, and therefore
Fig. 3 Jra antigen analysis by flow cytometry and family lineage. Jra antigen density was analyzed by flow cytometry, and the percentage of each
antigen density was shown with 376 C/C and 421C/C defined as 100 %
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in this type of HDN, hemoglobin levels are not maintained
in RBC, and hyperbilirubinemia is not present postpartum
or in the cord blood [16]. ABCG2 is believed to protect
cells from damage by heme by binding to heme in an
anaerobic state [17]. This function is consequently inhibited
by anti-Jra and may lead to anemia, in which no increase in
Fig. 4 Peripheral blood smear (a) and bone marrow fluid smear (c) at 3 days of age. Peripheral blood showed a few hypersegmented neutrophils
and megathrombocytes. Hyperplastic bone marrow was observed; however, no immature erythroblasts or megakaryocytes were found. Peripheral
blood smear (b) and bone marrow fluid smear (d) at 4 months of age. The hypersegmented neutrophils in peripheral blood disappeared, and no
megathrombocytes were observed. In the bone marrow, strongly basophilic immature erythroblasts were observed, and megakaryocytes appeared
normal. Both findings were observed using May-Giemsa staining
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hemoglobin is observed. Furthermore, as ABCG2 is
thought to regulate cellular differentiation, anti-Jra may
be involved in abnormal differentiation.
Conclusion
On the basis of the present study, we found that infants
can exhibit RBC with considerably low Jra antigen density
immediately postpartum, that Jra antigen density RBC may
be involved in aggravation of the condition, and that anti-
Jra may inhibit hematogenesis.
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